BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 126.2% in March

BrainsWay Ltd. (NASDAQ:BWAY) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 125,100 shares, a growth of 126.2% from the February 28th total of 55,300 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily volume of 65,800 shares, the short-interest ratio is presently 1.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research note on Wednesday, March 12th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BWAY. Valor Management LLC bought a new stake in shares of BrainsWay during the 4th quarter worth $19,838,000. Two Sigma Advisers LP boosted its position in shares of BrainsWay by 32.6% in the 4th quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock valued at $571,000 after purchasing an additional 14,900 shares during the period. Two Sigma Investments LP increased its stake in BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after purchasing an additional 1,786 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in BrainsWay during the 4th quarter worth about $44,000. Finally, Cubist Systematic Strategies LLC lifted its stake in BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after buying an additional 2,446 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

BrainsWay Price Performance

Shares of BWAY opened at $9.30 on Friday. The firm’s 50 day moving average is $10.27 and its 200-day moving average is $9.77. BrainsWay has a 12-month low of $4.61 and a 12-month high of $11.79. The stock has a market capitalization of $175.09 million, a P/E ratio of 93.01 and a beta of 1.29.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.